Cell line · CVCL_1245
Papers60
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling. | Cell Genom | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Computational pipeline predicting cell death suppressors as targets for cancer therapy. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. | Clin Transl Immunology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Type I interferon regulation by USP18 is a key vulnerability in cancer. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Revealing invisible cell phenotypes with conditional generative modeling. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1245/papers